2008
The insulin-like growth factor axis and risk of liver disease in hepatitis C virus/HIV-co-infected women
Strickler H, Howard A, Peters M, Fazzari M, Yu H, Augenbraun M, French A, Young M, Gange S, Anastos K, Kovacs A. The insulin-like growth factor axis and risk of liver disease in hepatitis C virus/HIV-co-infected women. AIDS 2008, 22: 527-531. PMID: 18301066, PMCID: PMC3507535, DOI: 10.1097/qad.0b013e3282f22cdf.Peer-Reviewed Original ResearchConceptsHIV-positive subjectsHIV-positive womenHepatic stellate cellsIGFBP-3Liver diseaseAPRI levelsLiver fibrosisInsulin-like growth factor binding protein 3Insulin-like growth factor (IGF) axisGrowth factor binding protein 3CD4 T-cell countWomen's Interagency HIV StudyLarge multi-institutional cohortInsulin-like growth factor IBaseline serum specimensHigher IGFBP-3T-cell countsHigh-risk patientsMulti-institutional cohortGrowth factor axisHepatitis C virusLiver function test dataGrowth factor IBinding protein 3Extracellular matrix accumulation
2004
Physicians’ Weight Loss Counseling in Two Public Hospital Primary Care Clinics
Huang J, Yu H, Marin E, Brock S, Carden D, Davis T. Physicians’ Weight Loss Counseling in Two Public Hospital Primary Care Clinics. Academic Medicine 2004, 79: 156-161. PMID: 14744717, DOI: 10.1097/00001888-200402000-00012.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAttitude of Health PersonnelClinical CompetenceCounselingDiabetes Mellitus, Type 2FemaleFocus GroupsHospitals, PublicHumansHyperlipidemiasInterviews as TopicLogistic ModelsLouisianaMaleMiddle AgedObesityOutpatient Clinics, HospitalPhysician's RolePractice Patterns, Physicians'Primary Health CareSampling StudiesWeight LossConceptsWeight loss counselingWeight loss recommendationsPrimary care clinicsPatient understandingWeight lossCare clinicsPatient recallLouisiana State University Health Sciences Center-ShreveportHospital primary care clinicPrimary care physiciansWeight loss strategiesRisk of obesityWeight management strategiesDistinct clinical diagnosisStage of readinessStructured exit interviewsObese patientsPhysician counselingCare physiciansPhysician barriersWeight managementLoss strategiesClinical diagnosisPatientsPhysicians
2003
Prevalence of Overweight, Obesity, and Associated Diseases among Outpatients in a Public Hospital
Huang J, Marin E, Yu H, Carden D, Arnold C, Davis T, Banks D. Prevalence of Overweight, Obesity, and Associated Diseases among Outpatients in a Public Hospital. Southern Medical Journal 2003, 96: 558-562. PMID: 12938782, DOI: 10.1097/01.smj.0000054725.35262.d4.Peer-Reviewed Original ResearchConceptsBody mass indexPrevalence of obesityPublic hospitalsLouisiana State University Health Sciences Center-ShreveportHigher body mass indexObesity-associated conditionsPercent of patientsTertiary health centerPrimary care patientsPublic hospital patientsPrevalence of overweightChronic medical conditionsObesity-related diseasesCross-sectional surveyStructure of careObese patientsCare patientsMass indexHospital patientsHealth centersMedical conditionsIndigent populationAssociated diseaseObesity ratesPatients
2000
Serum and Urinary Prostate-specific Antigen and Urinary Human Glandular Kallikrein Concentrations Are Significantly Increased after Testosterone Administration in Female-to-Male Transsexuals
Obiezu C, Giltay E, Magklara A, Scorilas A, Gooren L, Yu H, Howarth D, Diamandis E. Serum and Urinary Prostate-specific Antigen and Urinary Human Glandular Kallikrein Concentrations Are Significantly Increased after Testosterone Administration in Female-to-Male Transsexuals. Clinical Chemistry 2000, 46: 859-862. PMID: 10839777, DOI: 10.1093/clinchem/46.6.859.Peer-Reviewed Original ResearchConceptsUrinary prostate specific antigenProstate-specific antigenTestosterone administrationSerum prostate-specific antigenMale transsexualsMonths of treatmentMonths post treatmentHK2 concentrationsSerum hK2Testosterone treatmentAndrogen administrationAndrogenic stimulationKallikrein concentrationImmunofluorometric methodTime pointsHK2AdministrationMonthsWomenTreatmentPost treatmentAntigenCultured cellsFemalesCorresponding mean values
1998
The Acid-Labile Subunit of Human Ternary Insulin-Like Growth Factor Binding Protein Complex in Serum: Hepatosplanchnic Release, Diurnal Variation, Circulating Concentrations in Healthy Subjects, and Diagnostic Use in Patients with Growth Hormone Deficiency
Juul A, Møller S, Mosfeldt-Laursen E, Rasmussen M, Scheike T, Pedersen S, Kastrup K, Yu H, Mistry J, Rasmussen S, Müller J, Henriksen J, Skakkebæk N. The Acid-Labile Subunit of Human Ternary Insulin-Like Growth Factor Binding Protein Complex in Serum: Hepatosplanchnic Release, Diurnal Variation, Circulating Concentrations in Healthy Subjects, and Diagnostic Use in Patients with Growth Hormone Deficiency. The Journal Of Clinical Endocrinology & Metabolism 1998, 83: 4408-4415. PMID: 9851786, DOI: 10.1210/jcem.83.12.5311.Peer-Reviewed Original ResearchConceptsAcid-labile subunitIGFBP-3GH deficiencyALS levelsHepatosplanchnic releaseNormal age-related rangesChildhood-onset GH deficiencyInsulin-like growth factorAge-related rangeSignificant arteriovenous gradientNormal GH responseGH secretory statusConcentrations of IGFLiver vein catheterizationGrowth hormone deficiencyCirculating ConcentrationsGH responseGHD patientsVein catheterizationSecretory statusArteriovenous gradientHormone deficiencyHealthy subjectsDiagnostic utilityIGF
1997
Prostate-Specific Antigen in Female Serum, a Potential New Marker of Androgen Excess
Melegos D, Yu H, Ashok M, Wang C, Stanczyk F, Diamandis E. Prostate-Specific Antigen in Female Serum, a Potential New Marker of Androgen Excess. The Journal Of Clinical Endocrinology & Metabolism 1997, 82: 777-780. PMID: 9062481, DOI: 10.1210/jcem.82.3.3792.Peer-Reviewed Original ResearchConceptsProstate-specific antigenMarker of androgen excessSerum prostate-specific antigenHirsute womenReceiver operating characteristicAndrogen actionAndrogen excessLevels of prostate-specific antigenProstate-specific antigen levelProstate-specific antigen geneFemale serumAction of steroid hormone receptorsMarker of androgen actionAlpha-androstanediol glucuronideSerum PSA levelsFerriman-Gallwey scorePotential new markerSteroid hormone receptorsPSA levelsProstate-specificHyperandrogenic statePatient ageAlpha-androstanediolAlpha-AgBiochemical markers
1996
Circulating antibodies against p53 protein in patients with ovarian carcinoma
Angelopoulou K, Rosen B, Stratis M, Yu H, Solomou M, Diamandis E. Circulating antibodies against p53 protein in patients with ovarian carcinoma. Cancer 1996, 78: 2146-2152. PMID: 8918407, DOI: 10.1002/(sici)1097-0142(19961115)78:10<2146::aid-cncr15>3.0.co;2-z.Peer-Reviewed Original ResearchConceptsAntibody-positive patientsOvarian carcinomaP53 antibodiesP53 autoantibodiesPositive patientsSuch antibodiesMultivariate analysisPatient disease-free survivalKaplan-Meier survival curvesSerum p53 antibodiesTumor p53 overexpressionDisease-free survivalOlder patient ageSubset of patientsTumor histologic typeOverall patient survivalSera of patientsFrequent molecular eventUnits/LFree survivalNegative patientsOverall survivalPatient ageSuch autoantibodiesAntibody levelsProstate specific antigen in breast cancer, benign breast disease and normal breast tissue
Yu H, Diamandis E, Levesque M, Giai M, Roagna R, Ponzone R, Sismondi P, Monne M, Croce C. Prostate specific antigen in breast cancer, benign breast disease and normal breast tissue. Breast Cancer Research And Treatment 1996, 40: 171-178. PMID: 8879683, DOI: 10.1007/bf01806212.Peer-Reviewed Original ResearchConceptsBenign breast diseaseProstate-specific antigenNormal breast tissueBreast diseaseBreast tumorsBreast tissueBreast cancerSpecific antigenBreast cancer tissuesSteroid hormone actionPSA positivityPSA levelsDisease stageProstatic adenocarcinomaPSA productionTumor markersStage IBBD tissueCancer tissuesFemale breastSteroid hormonesLow expressionPolymerase chain reaction amplificationTumorsChain reaction amplification
1995
Original Articles: Prostate Cancer: Measurement of Serum Prostate Specific Antigen Levels in Women and in Prostatectomized Men With an Ultrasensitive Immunoassay Technique
Yu H, Diamandis E. Original Articles: Prostate Cancer: Measurement of Serum Prostate Specific Antigen Levels in Women and in Prostatectomized Men With an Ultrasensitive Immunoassay Technique. Journal Of Urology 1995, 153: 1004-1008. PMID: 7531781, DOI: 10.1016/s0022-5347(01)67622-5.Peer-Reviewed Original ResearchConceptsSerum prostate-specific antigenProstate-specific antigenPSA levelsDetectable serum prostate specific antigenDistribution of PSAHigher serum prostate-specific antigenSerum prostate-specific antigen levelHealthy female blood donorsMeasurable prostate-specific antigenPostoperative prostate-specific antigenPreoperative prostate-specific antigenProstate-specific antigen levelYear of surgeryEvidence of relapseFemale blood donorsSpecific antigen levelsAge 50 yearsProstate cancer patientsHospitalized womenPatients 50Recurrent tumorsAntigen levelsHistological gradeCancer patientsRadical prostatectomy
1993
Ultrasensitive time-resolved immunofluorometric assay of prostate-specific antigen in serum and preliminary clinical studies.
Yu H, Diamandis E. Ultrasensitive time-resolved immunofluorometric assay of prostate-specific antigen in serum and preliminary clinical studies. Clinical Chemistry 1993, 39: 2108-2114. PMID: 7691442, DOI: 10.1093/clinchem/39.10.2108.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAlkaline PhosphataseAntibodies, MonoclonalChromatography, High Pressure LiquidEdetic AcidFemaleFluoroimmunoassayHumansMaleMiddle AgedNeoplasm Recurrence, LocalProstate-Specific AntigenProstatectomyProstatic NeoplasmsQuality ControlReference ValuesSensitivity and SpecificityTerbiumConceptsL PSAPolyclonal detection antibodyUltrasensitive time-resolved immunofluorometric assaySensitive prostate specific antigenPSA antibodyDetection antibodyTime-resolved fluorometryTime-resolved immunofluorometric assayUltrasensitive methodProstate-specific antigenMicrotiter wellsImmunofluorometric assayClinical applicationStreptavidinExtreme sensitivityAssays